Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Autoimmune Partnering 2010-2016: Deal Trends, Players and Financials - Research and Markets

Research and Markets
Posted on: 06 Oct 16

Research and Markets has announced the addition of the "Global Autoimmune Partnering 2010-2016: Deal trends, players and financials" report to their offering.

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

Global Autoimmune Partnering 2010 to 2016 provides

  • Trends in Autoimmune partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Autoimmune partnering agreement structure
  • Autoimmune partnering contract documents
  • Top Autoimmune deals by value
  • Most active Autoimmune dealmakers

The report includes coverage of the following autoimmune diseases:

  • Multiple sclerosis
  • Restless leg syndrome
  • Eczema
  • Alopecia
  • Psoriasis
  • Celiac disease
  • Inflammatory bowel disease
  • Crohn's disease
  • Ulcerative colitis
  • Glomerulonephritis
  • Endometriosis
  • Immune thrombocytopenic purpura
  • Neutropenia
  • Graft versus host disease
  • Scleroderma
  • Systemic lupus erythematosus
  • Addison's disease
  • Diabetes Type 1
  • Ankylosing spondylitis
  • Juvenile arthritis
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Uveitis
  • Narcolepsy
  • Idiopathic pulmonary fibrosis
  • Sarcoidosis
  • Meniere's disease

The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Autoimmune dealmaking

Chapter 3 - Financial deal terms for Autoimmune partnering

Chapter 4 - Leading Autoimmune deals and dealmakers

Chapter 5 - Autoimmune contract document directory

Chapter 6 - Autoimmune dealmaking by therapeutic target

For more information about this report visit

View source version on

Business Wire

Last updated on: 06/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.